Last updated: July 7, 2026
Exelixis v. Handa Pharmaceuticals (1:26-cv-00813): Litigation Summary, Claims, Timeline, and Likely Case Posture
Exelixis, Inc. v. Handa Pharmaceuticals, Inc., case number 1:26-cv-00813, is pending in federal court. The publicly available record provided here is insufficient to extract the legally operative details needed for a reliable litigation summary and analysis (asserted patents, claim construction, parties’ positions, procedural milestones, and outcomes). No actionable patent or motion-to-dismiss/Markman/settlement record can be stated without risking fabrication.
What patents are asserted in Exelixis v. Handa Pharmaceuticals (1:26-cv-00813)?
Answer: Not provided in the available material.
Which Orange Book patents or listed drug-product patents are in-scope
Answer: Not provided in the available material.
How many patents are asserted and what patent types
Answer: Not provided in the available material.
- Method-of-use vs. composition-of-matter vs. formulation vs. manufacturing patents: not available.
What is the procedural posture of 1:26-cv-00813?
Answer: Not provided in the available material.
What filings exist (complaint, answer, amended complaint)
Answer: Not provided in the available material.
Are there motions to dismiss or venue/standing challenges?
Answer: Not provided in the available material.
Has there been a Markman (claim-construction) schedule?
Answer: Not provided in the available material.
Have there been claim amendments, stipulations, or protective orders?
Answer: Not provided in the available material.
Why did Exelixis sue Handa Pharmaceuticals: Paragraph IV, injunction, or declaratory relief?
Answer: Not provided in the available material.
Is this a Hatch-Waxman Act (HWA) suit with an ANDA trigger?
Answer: Not provided in the available material.
Is there a biosimilar pathway issue (BLA/351(k))?
Answer: Not provided in the available material.
Is the case focused on non-infringement, invalidity, or both?
Answer: Not provided in the available material.
When does the infringement theory target the generic/competitor product?
Answer: Not provided in the available material.
What dosage form and strength are accused
Answer: Not provided in the available material.
What launch year would be at risk if infringement is found
Answer: Not provided in the available material.
What does the complaint allege about non-infringement and invalidity?
Answer: Not provided in the available material.
Claim-by-claim positions
Answer: Not provided in the available material.
Common invalidity grounds (101/102/103/112) raised
Answer: Not provided in the available material.
Written description and enablement challenges
Answer: Not provided in the available material.
What settlement, consent judgment, or stipulations typically follow in cases like 1:26-cv-00813?
Answer: Not provided in the available material.
Whether a 30-month stay or other timing relief is in play
Answer: Not provided in the available material.
Whether a license agreement is reported
Answer: Not provided in the available material.
How strong is the patent estate asserted in Exelixis v. Handa Pharmaceuticals?
Answer: Not provided in the available material.
Patent age and likely remaining term
Answer: Not provided in the available material.
Prior office actions, continuations, and claim scope
Answer: Not provided in the available material.
Litigation history for the same family
Answer: Not provided in the available material.
What generic entry risks exist for Handa Pharmaceuticals if the case is dismissed or narrowed?
Answer: Not provided in the available material.
Risks from claim construction outcomes
Answer: Not provided in the available material.
Risks from a non-infringement finding
Answer: Not provided in the available material.
Risks from invalidity determinations
Answer: Not provided in the available material.
What is the injunction posture: temporary restraining order (TRO) or preliminary injunction?
Answer: Not provided in the available material.
Whether Exelixis sought immediate injunctive relief
Answer: Not provided in the available material.
Whether courts issued or denied interim relief
Answer: Not provided in the available material.
Comparison: How does Exelixis’s litigation strategy here compare with other Exelixis patent cases?
Answer: Not provided in the available material.
Typical forum choices and procedural patterns
Answer: Not provided in the available material.
Typical settlement terms and product-scope constraints
Answer: Not provided in the available material.
Key Takeaways
- 1:26-cv-00813 is pending, but no operative litigation record is available here to support a fact-based summary of asserted patents, claims, procedural milestones, or case outcomes.
- No reliable analysis can be produced on infringement theories, invalidity defenses, claim construction, injunction posture, or exclusivity/timing impacts without the underlying court docket content and complaint/briefing.
FAQs
-
What is the court and judge for Exelixis v. Handa Pharmaceuticals (1:26-cv-00813)?
Not provided in the available material.
-
Which Exelixis patents does Handa Pharmaceuticals allegedly infringe in 1:26-cv-00813?
Not provided in the available material.
-
Does 1:26-cv-00813 allege a Paragraph IV certification and an ANDA challenge?
Not provided in the available material.
-
Has the court set a Markman date or issued claim-construction rulings in 1:26-cv-00813?
Not provided in the available material.
-
What is the most recent docket event and what does it indicate about settlement likelihood?
Not provided in the available material.
References
Not provided.
